Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dehydroepiandrosterone + somatotropin
- Development stage
- Unknown
- Lead developer
- Cairo University
- Modality
- Peptides, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
Dehydroepiandrosterone (DHEA) + somatotropin is a combination therapy being evaluated by Cairo University for the treatment of subfertility, specifically in women with expected poor ovarian response undergoing intracytoplasmic sperm injection (ICSI). Somatotropin, a recombinant human growth hormone, acts as an agonist at the growth hormone receptor (GHR), stimulating the production of insulin-like growth factor-1 (IGF-1) within the ovarian microenvironment. This enhances the sensitivity of follicles to follicle-stimulating hormone (FSH) and may improve oocyte quality. DHEA is a steroid hormone precursor that is converted into androgens and estrogens, which are thought to increase the pool of recruitable preantral and antral follicles and improve the ovarian response to stimulation. This combination is typically administered as an adjuvant to standard controlled ovarian hyperstimulation protocols.
- Other names
- GH + DHEAGrowth Hormone + DehydroepiandrosteroneSomatotropin + DHEA
02
Targets
ESR1 (ERα)GHR (Growth hormone receptor)ESR2 (ERβ)AR (Adrenergic receptors)
Beyond the preview
Go deeper on dehydroepiandrosterone + somatotropin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dehydroepiandrosterone + somatotropin.